We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

IMPAX Receives Final FDA Approval for Generic Version of Claritin-D 24-Hour

Law360 (March 5, 2004, 12:00 AM EST) -- The U.S. Food and Drug Administration has granted final approval to Impax Laboratories' Abbreviated New Drug Application (ANDA) for a generic version of Schering-Plough’s Claritin(R)-D 24-Hour Extended Release Tablets, Impax said.

The company said it filed the ANDA with a Paragraph IV certification under the Hatch-Waxman Amendments, indicating it is challenging the validity of Schering-Plough’s patent for the drug.

Generics drug applicants must include with ANDAs a statement addressing the generic drug's relationship to each Orange Book-listed patent of the original branded drug. Paragraph IV certifications...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.